KPV

Dosing from the Literature

Published for inflammation: mouse doses only, by mouth: 100 μM KPV in the drinking water (Dalmasso et al., 2008; PMID 18061177), or 16 μg/kg a day inside nanoparticles (Xiao et al., 2017; PMC5498804). Not published: any human dose; no human trial exists.

In the mouse colitis studies KPV was given by mouth: 100 μM in the drinking water for 2–8 days (Dalmasso et al., 2008; PMID 18061177) or through two 7-day rounds of colitis in a colitis-associated cancer model (Viennois et al., 2016), and 16 μg/kg a day inside nanoparticles, by gavage, during colitis (Xiao et al., 2017; PMC5498804). The human figures below are what online guides describe; no trial has tested them, and the guides disagree.

What It Is

KPV is a tripeptide (a chain of 3 amino acids) consisting of lysine-proline-valine (Lys-Pro-Val). It is the C-terminal tripeptide fragment of α-melanocyte-stimulating hormone (α-MSH) — specifically residues 11–13 of the parent 13-amino-acid α-MSH sequence. The broader α-MSH molecule has potent anti-inflammatory and immunomodulatory (adjusting the immune system up or down) effects, thought to act mainly through melanocortin receptors, MC1R in particular (Luger & Brzoska, 2007). The surprise finding, developed across a series of papers by the Luger group in Münster and the Dalmasso/Merlin group at Emory, was that the tripeptide KPV retained the anti-inflammatory activity of α-MSH while explicitly NOT requiring melanocortin receptor engagement. The anti-inflammatory effect is mediated through PepT1 (the intestinal peptide transporter) and downstream NF-κB (a master inflammation switch) pathway inhibition — a mechanism that operates entirely independent of the melanocortin receptor family.

This mechanism matters for two reasons. First, it explains why KPV is orally bioavailable — PepT1 is the major intestinal oligopeptide transporter, and KPV is a good substrate. Oral α-MSH (the hormone that tells skin to tan) would be degraded; oral KPV is absorbed. Second, it means KPV does not produce the melanocortin-receptor-mediated effects of α-MSH and its analogs — no pigmentation, no sexual effects, no appetite suppression, no BP elevation. The phenotype is narrowly anti-inflammatory with minimal off-target pharmacology, which is unusual for bioactive peptides in the optimization space.

The Dalmasso et al. 2008 Gastroenterology paper (PMID 18061177) established KPV as a PepT1-mediated anti-inflammatory tripeptide in two mouse colitis models (DSS-induced and TNBS-induced), and Kannengiesser et al. 2008 (PMID 18092346) replicated the effect in additional IBD models from a separate research group. Since then, KPV has been explored in preclinical models of ulcerative colitis, Crohn's disease, atopic dermatitis, psoriasis, ocular inflammation, and general skin inflammation. In the community optimization space, KPV has become one of the most-used anti-inflammatory peptides, particularly for IBD-spectrum gut conditions and chronic skin inflammation, and online guides pair it with BPC-157.

As of April 2026, KPV has no published Phase 2 or Phase 3 human clinical trial for any indication. Community use is extrapolated from the preclinical literature and from α-MSH's broader immunomodulatory profile. The mechanism is well-established at the bench level; the clinical endpoint validation in humans is still pending.

Mechanism of Action

What is known of KPV's mechanism comes from human cell lines and mouse studies (Dalmasso et al., 2008; PMID 18061177; Kannengiesser et al., 2008; PMID 18092346); no human study has tested it.

• PepT1-mediated cellular uptake — KPV is a substrate for PepT1 (SLC15A1), the di- and tri-peptide transporter normally expressed in the small intestine and induced in the colon during inflammatory bowel disease. In human gut and T-cell lines, PepT1 carried KPV into the cells, and KPV's anti-inflammatory effect was lost in cells without PepT1 or when another PepT1 substrate competed with it (Dalmasso et al., 2008; PMID 18061177).
• NF-κB pathway inhibition — In human gut epithelial cells stimulated with IL-1β, 10 nM KPV reduced and shortened the activation of NF-κB, a transcription factor that switches on inflammatory genes, and cut IL-8 mRNA by about 35% (Dalmasso et al., 2008; PMID 18061177).
• MAPK pathway inhibition — In the same cells, KPV strongly reduced IL-1β-triggered activation of the p38, ERK1/2 and JNK MAP kinases; the authors call the NF-κB and MAPK pathways the classical routes to cytokine secretion in inflamed gut cells (Dalmasso et al., 2008; PMID 18061177).
• Pro-inflammatory cytokine reduction — KPV lowered IL-8 in human gut and T-cell lines, and in mice with chemically induced colitis it lowered colonic mRNA for IL-6 and IL-12 (DSS model) and for IL-1β, IL-6, TNF-α and IFN-γ (TNBS model) (Dalmasso et al., 2008; PMID 18061177).
• Non-melanocortin-receptor mechanism — Binding studies suggest KPV does not bind MC1R, the receptor that controls skin pigment, and it fails to raise cAMP, the signal melanocortin receptors send (Luger & Brzoska, 2007; PMC2095288); a study cited by Dalmasso et al. found no binding to MC1R, MC3R or MC5R (Dalmasso et al., 2008; PMID 18061177). In mice without a working MC1R, KPV still protected against DSS colitis, so its effect seems at least partly independent of MC1R (Kannengiesser et al., 2008; PMID 18092346). A 2008 review describes KPV as keeping α-MSH's anti-inflammatory effect without its pigmentary action (Brzoska et al., 2008; PMID 18612139).
• Mucosal healing — Loaded into nanoparticles, KPV sped the healing of wounded human gut-cell layers in a dish, and given by mouth to mice with colitis it limited damage to the colon lining (Xiao et al., 2017; PMC5498804).
• T-cell modulation — In a human T-cell line (Jurkat), PepT1 carried KPV into the cells, where it partly blocked TNF-α-triggered NF-κB activation and lowered IL-8 mRNA (Dalmasso et al., 2008; PMID 18061177).
• Anti-microbial activity (α-MSH heritage) — KPV, like α-MSH, has shown antimicrobial activity against Staphylococcus aureus and the yeast Candida albicans (Luger & Brzoska, 2007; PMC2095288).
• PepT1 upregulation in disease — PepT1 is scarce in the healthy colon but appears on the lining of chronically inflamed colon, and macrophages carry it too; the authors suggest this could let oral KPV reach inflamed colon cells (Dalmasso et al., 2008; PMID 18061177).

What the Research Shows

The KPV preclinical evidence base is focused and mechanistically coherent, concentrated around inflammatory bowel disease and skin inflammation.

• PepT1-mediated anti-colitis (Dalmasso et al., Gastroenterology 2008; PMID 18061177) — Foundational paper establishing PepT1-mediated KPV uptake and anti-inflammatory effect in DSS- and TNBS-induced colitis. Showed oral KPV significantly reduced colonic inflammation markers.
• IBD model efficacy (Kannengiesser et al., Inflamm Bowel Dis 2008; PMID 18092346) — Independent replication from the Luger group in Münster. Melanocortin-derived tripeptide KPV showed anti-inflammatory potential in murine models of inflammatory bowel disease. Reduction in colonic damage and inflammatory cytokines.
• Alpha-MSH (the hormone that tells skin to tan) anti-inflammatory review (Luger et al., Ann N Y Acad Sci) — Broader framework placing KPV within the α-MSH anti-inflammatory family.
• PepT1 in colitis-associated cancer (Cell Mol Gastroenterol Hepatol 2016) — Demonstrated therapeutic benefit of PepT1-mediated KPV in colitis-associated cancer mouse model.
• Hyaluronic-acid nanoparticle delivery (Xiao et al., 2017; PMC5498804) — Orally targeted delivery of KPV via HA-functionalized nanoparticles efficiently alleviated ulcerative colitis in mouse model. Proof-of-concept for targeted delivery formulation.
• Core/C-terminal α-MSH dissection — Research dissecting the anti-inflammatory activity of core and C-terminal (KPV) α-MSH peptides established that the C-terminal KPV retains the anti-inflammatory effect without requiring melanocortin receptor binding.
• Skin inflammation / atopic dermatitis — Preclinical studies showing KPV reduces atopic dermatitis-type inflammation in mouse models; mechanism involves mast cell stabilization and cytokine reduction.
• Keratinocyte NF-κB inhibition — Cell culture studies demonstrating KPV reduces inflammatory cytokine production in keratinocytes under TNF-α stress and fine-particulate exposure.
• Psoriasis models — Preclinical reports of topical KPV reducing psoriasiform inflammation in mouse models.
• Ocular inflammation (anterior uveitis) — Preclinical work on KPV-family peptides in ocular inflammation models.
• Wound healing (anti-inflammatory component) — Complementary role of KPV in the resolution phase of wound healing via inflammation control.
• Anti-microbial activity — Modest direct anti-bacterial activity against some pathogens; inherited from α-MSH.

Human Data

Human evidence for KPV is minimal:

• Alpha-MSH in humans (parent molecule) — Elevated endogenous α-MSH observed in some inflammatory conditions as a counter-regulatory response. Provides indirect support for the anti-inflammatory framework.
• No published Phase 1 pharmacokinetic study of KPV specifically — Surprising gap given the preclinical enthusiasm. PepT1 substrate pharmacokinetics in humans is extrapolated from general PepT1 pharmacology.
• No Phase 2 or Phase 3 RCT — For any indication, including IBD, UC, CD, atopic dermatitis, or psoriasis.
• Open-label and case-report community use — Accumulated practitioner experience in IBD, gut inflammation, allergic skin conditions, and allergic asthma. Not validated endpoint data.
• KPV-containing topical formulations — Commercial cosmetic and wound-healing products containing KPV exist. Limited clinical endpoint data.
• Nanoparticle-targeted delivery trials — Emerging pharmaceutical development of HA-nanoparticle-targeted KPV; preclinical only as of April 2026.

This evidence gap is the central limitation of KPV's profile. The preclinical mechanism and data are strong; the human clinical validation is thin. The compound has been used in community settings for ~15 years without a Phase 2 program materializing — likely a combination of funding challenges (small tripeptides don't fit large-pharma economics) and the absence of regulatory incentive to develop it.

Reconstitution & Storage

Sellers list KPV as a lyophilized (freeze-dried) powder in 5 mg, 10 mg and other vial sizes, and some sell 250 μg capsules. Online guides describe mixing the powder with bacteriostatic water.

• Reconstitution — Online guides describe adding the water slowly down the inside wall of the vial and swirling gently, not shaking.
• SubQ administration — Online guides describe 29–31 gauge insulin syringes, injection into the abdomen, outer thigh or upper arm, and rotating sites.
• Storage — Seller and guide listings disagree for the dry powder, from room temperature to −20°C. For the mixed solution, guides list 2–8°C and use within 3–4 weeks.
• Timing — Online guides describe oral doses on an empty stomach, about 30 minutes before food, reasoning that peptides from food compete for PepT1.

→ Calculator — vial-to-syringe math

Side Effects & Risks

No human study of KPV has been published and none is registered on ClinicalTrials.gov, so its side effects in people are unknown. A 2007 review said the adverse effects of α-MSH-related tripeptides "seem to be minimal" on preliminary toxicity and safety data (Luger & Brzoska, 2007).

• Reported side effects — No study in people has recorded any. Online guides relay user reports of mild redness or irritation at the injection site, passing stomach upset with oral use and, less often, headache.
• No pigmentation effect — A 2008 review describes KPV as lacking α-MSH's pigmentary action (Brzoska et al., 2008), and binding studies suggest it does not bind MC1R, the pigment receptor (Luger & Brzoska, 2007).
• Immunosuppression concern (theoretical) — Because KPV lowered inflammatory cytokines in cells and mice (Dalmasso et al., 2008; PMID 18061177), long or high-dose use could in theory blunt normal immune responses; untested in people. A 2007 review expects no strong immunosuppression from α-MSH-related peptides: in lab studies they reduced but never fully blocked NF-κB activation, and had little effect without an inflammatory trigger (Luger & Brzoska, 2007).
• Drug interactions — Untested. In cells, KPV competed with another substrate for PepT1, which also carries various peptide-derived drugs (Dalmasso et al., 2008; PMID 18061177), so interactions with such drugs are possible in theory.
• Pregnancy / lactation — Not studied.
• Active infection — In theory, a weaker cytokine response could impair control of an infection; untested in people. The 2007 review argues the infection risk may be lower than with conventional immunosuppressants, citing the peptides' antimicrobial activity (Luger & Brzoska, 2007).
• Purity / sourcing — Sellers list KPV for laboratory research use only and state that it is not a drug and has not been evaluated by the FDA.
• Regulatory status — Not FDA-approved; not scheduled. Research-chemical supply.
• WADA status — Not specifically listed.

Quick Compare — KPV vs BPC-157 vs Alpha-MSH vs Afamelanotide

The most relevant comparators are BPC-157 (gut-healing peptide with overlapping IBD use case), the parent α-MSH molecule, and afamelanotide (FDA-approved α-MSH analog for EPP).

Practical interpretation:

• KPV vs BPC-157 — Different mechanisms (NF-κB inhibition vs growth factor / angiogenic signaling). Online guides pair them as a gut stack, and sellers combine them in the KLOW blend; no published study has tested the two together.
• KPV vs α-MSH — KPV retains α-MSH's anti-inflammatory activity without the melanocortin-receptor-mediated side effects (pigmentation, sexual, BP). α-MSH itself is not pharmaceutically used.
• KPV vs afamelanotide — Different use cases entirely. Afamelanotide is a photoprotection drug for EPP; KPV is an anti-inflammatory research peptide.

→ See BPC-157 profile  •  → See Afamelanotide profile  •  → See PT-141 profile

Bloodwork & Monitoring

No trial, label or guideline sets monitoring for KPV, and no human study of it has been published. The mouse colitis studies tracked body weight, colon histology and length, myeloperoxidase activity (a marker of neutrophils in the colon) and colonic cytokine mRNA (Dalmasso et al., 2008; PMID 18061177; Kannengiesser et al., 2008).

Commonly Stacked With

Stacking this? Read the receipt →

→ Calculator — vial-to-syringe math

Legal Status

Related Compounds

Anti-inflammatory and repair peptides that sit alongside or overlap with KPV's niche.

Next Steps

References

1. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. PMID: 18061177.
2. Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, Bohm M, Luger TA, Domschke W, Kucharzik T. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. PMID: 18092346.
3. Luger TA, Brzoska T. alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Ann Rheum Dis. 2007;66 Suppl 3:iii52-iii55. PMC2095288.
4. Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. α-Melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008;29(5):581-602. PMID: 18612139.
5. Coco R, Plapied L, Pourcelle V, Jérôme C, Brayden DJ, Schneider YJ, Préat V. Drug delivery to inflamed colon by nanoparticles: comparison of different strategies. Int J Pharm. 2013;440(1):3-12. PMID: 22820482.
6. Xiao B, Laroui H, Viennois E, et al. Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice. Gastroenterology. 2014;146(5):1289-1300.e1-19. PMID: 24503126.
7. Viennois E, Ingersoll SA, Ayyadurai S, et al. Critical Role of PepT1 in Promoting Colitis-Associated Cancer and Therapeutic Benefits of the Anti-inflammatory PepT1-Mediated Tripeptide KPV in a Murine Model. Cell Mol Gastroenterol Hepatol. 2016;2(3):340-357. PMID: 27458604.
8. Xiao B, Xu Z, Viennois E, Zhang Y, Zhang Z, Zhang M, Han MK, Kang Y, Merlin D. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Mol Ther. 2017;25(7):1628-1640. PMC5498804.
9. Lee S, Lee SJ, Shin H, et al. α-MSH-derived tripeptide KPV reduces TNF-α induced inflammation in keratinocytes via NF-κB pathway modulation. J Dermatol Sci. 2019.
10. Ahmed TJ, Montero-Melendez T, Perretti M, Pitzalis C. Curbing inflammation through endogenous pathways: focus on melanocortin peptides. Int J Inflam. 2013;2013:985815. PMID: 23738228.
11. Singh M, Mukhopadhyay K. Alpha-melanocyte stimulating hormone: an emerging anti-inflammatory antimicrobial peptide. Biomed Res Int. 2014;2014:874610. PMID: 25140322.
12. Bohm M, Brzoska T, Luger TA. Anti-inflammatory effects of alpha-MSH and related peptides: beyond the pharmacophore. Adv Exp Med Biol. 2010;681:55-64.
13. Shi X, Chen X, Gao X, et al. Immobilized α-melanocyte stimulating hormone 10–13 (GKPV) inhibits tumor necrosis factor-α stimulated NF-κB activity. Peptides. 2006.
14. Capsoni F, Ongari AM, Reali E, Catania A. Melanocortin peptides inhibit urate crystal-induced activation of phagocytic cells. Arthritis Res Ther. 2009;11(5):R151. PMID: 19814819.
15. Brzoska T, Böhm M, Lügering A, Loser K, Luger TA. Terminal signal: anti-inflammatory effects of α-MSH-related peptides beyond the pharmacophore. Adv Exp Med Biol. 2010;681:107-116.
16. Getting SJ, Perretti M. The melanocortin peptide HP228 displays protective and anti-inflammatory activity in models of experimental inflammation. Br J Pharmacol. 2000;130(8):1889-1896.
17. Catania A, Airaghi L, Colombo G, Lipton JM. Alpha-melanocyte-stimulating hormone in normal human physiology and disease states. Trends Endocrinol Metab. 2000;11(8):304-308. PMID: 10996524.
18. Kannengiesser K, Lügering A, Maaser C, Domschke W, Luger TA, Kucharzik T. Treatment of murine colitis with the tripeptide KPV-review of recent findings. Falk Symp. 2010.
19. Dalmasso G, Nguyen HT, Yan Y, Charrier-Hisamuddin L, Sitaraman SV, Merlin D. Butyrate transcriptionally enhances peptide transporter PepT1 expression and activity. PLoS One. 2008;3(6):e2476. PMID: 18575574.
20. Xiao B, Ma L, Merlin D. Nanoparticle-mediated co-delivery of chemotherapeutic agent and siRNA for combination cancer therapy. Expert Opin Drug Deliv. 2017;14(1):65-73. PMID: 27337289.
21. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (503A categories list), versions updated April 15, April 22 and May 14, 2026. fda.gov/media/94155/download. Read October 3, 2026. (Notice that 12 peptides would leave Category 2 because their nominations were withdrawn; their removal; GHK-Cu, except injectable, back in Category 1.)
22. Clinuvel Inc. SCENESSE (afamelanotide) implant, for subcutaneous use. Prescribing information. DailyMed set ID 94f53286-11dd-7fbb-e053-2a95a90a7c48 (version 11, effective May 11, 2026). dailymed.nlm.nih.gov. Read October 3, 2026.

Related Research

• LL-37Human Cathelicidin / Antimicrobial Host Defense
• LivagenKhavinson Lymphoid / Hepatic Bioregulator
• Neurokinin ATachykinin Neuropeptide (NK2R Agonist)
• ThymagenKhavinson Thymic Immune Bioregulator
• KLOW StackBPC-157 · GHK-Cu · KPV · TB-500 — gut healing protocol
• FDA TrackerKPV was removed from Category 2 on April 22, 2026 (FDA notice April 15, 2026). PCAC recommended it on July 23–24, 2026. Rulemaking pending — not legal to compound today.